Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 2, March-April, p. 307–313

doi: 10.17219/acem/40465

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Dimethylarginines as Risk Markers of Atherosclerosis and Chronic Kidney Disease in Children with Nephrotic Syndrome

Lidia Hyla-Klekot1,A,B,C,D,E,F, Piotr Bryniarski2,A,B,C,D,E,F, Barbara Pulcer1,A,B,C,D,E,F, Katarzyna Ziora3,D,F, Andrzej Paradysz2,A,C,D

1 Chorzow Center of Pediatrics and Oncology, Chorzów, Poland

2 Department of Urology, Medical University of Silesia, Zabrze, Poland

3 Department and Clinic of Pediatrics, Medical University of Silesia, Zabrze, Poland

Abstract

Background. Nephrotic syndrome in children is commonly associated with dyslipidemia, which is considered a risk factor for endothelial dysfunction and atherosclerosis. Recently new markers of endothelial dysfunction, such as asymmetric dimethylarginine (ADMA), have gained importance. Another L-arginine derivative – symmetric dimethylarginine (SDMA) – may reflect the glomerular filtration rate (GFR).
Objectives. The main aim of this study was to assess ADMA as a marker of atherosclerosis. Secondly, SDMA was examined for GFR assessment.
Material and Methods. The study involved 32 children with nephrotic syndrome. Several parameters were examined in the remission and relapse phases of nephrotic syndrome, including ADMA, SDMA, cholesterol, triglycerides and GFR.
Results. In the relapse phase there was a negative correlation between ADMA and lipids (cholesterol and triglycerides). In both phases SDMA was negatively correlated with GFR.
Conclusion. The role of ADMA as a marker for endothelial dysfunction is not significant. SDMA may be utilized to monitor GFR in children with nephrotic syndrome.

Key words

nephrotic syndrome, ADMA, SDMA, endothelial function, GFR, atherosclerosis.

References (42)

  1. Trocha M, Merwid A, Szuba A, Sozański T, Magdalan J, Szeląg A: Asymmetric dimetylarginine synthesis and degradation under physiological and pathological conditions. Adv Clin Exp Med 2010, 19, 233–243.
  2. Maas R, Schwedhelm E, Kahl L, Li H, Benndorf R, Lüneburg N, Förstermann U, Böger RH: Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem 2008, 54, 292–300.
  3. Billecke SS, D’Alecy LG, Platel R, Whitesall SE, Jamerson KA, Perlman RL, Gadegbeku CA: Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol Dial Transplant 2009, 24, 489–496.
  4. Caplin B, Nitsch D, Gill H, Hoefield R, Blackwell S, MacKenzie D, Cooper JA, Middleton RJ, Talmud PJ, Veitch P, Norman J, Wheeler DC, Leiper JM: Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. Kidney Int 2010, 77, 459–467.
  5. Tomohiro O, Masayuki S, Satoko S, Hirofumi T, Toshiro M, Okumura K: Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003, 42, 985–990.
  6. Zoccali C: Asymmetric dimethylarginine in end – stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism? Kidney Int 2006, 70, 2053–2055.
  7. Horl W: Miażdżyca a toksyny mocznicowe. Forum nefrologiczne. Kidney Int 2006, 2, 63–78.
  8. Glorieux G, Schepers E, Meert N, Vanholder R: Uraemic toxins in chronic kidney disease. Port J Nephrol Hypert 2008, 22, 287–302.
  9. Abedini S, Meinitzer A, Holme I, März W, Weihrauch G, Fellstrøm B, Jardine A, Holdaas H: Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010, 77, 44–50.
  10. Ardigo D, Stüehlinger M, Franzini L, Valtueña S, Piatti PM, Pachinger O, Reaven GM, Zavaroni I: ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 2007, 37, 263–269.
  11. Kielstein J, Zoccali C: Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hyperten 2008, 17, 609–615.
  12. Doroszko A, Andrzejak R, Szuba A: Dysfunkcja śródbłonka w patogenezie nadciśnienia tętniczego. Arterial Hypertension 2008, 12, 224–237.
  13. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D: Symmetric dimethylarginine (SDMA) as endogenous marker of renal function – a meta-analysis. Nephrol Dial Transplant 2006, 21, 2446–2451.
  14. Książek J, Ciechanowicz A, Wierzbicka A, Syczewska M, Grenda R: Is dyslipidemia sustained during remission of nephrotic syndrome genetically determined? Pol Arch Med Wewn 2008, 179, 11–17.
  15. Kuźma E, Roszkowska-Blaim M: Zaburzenia lipidowe u dzieci z nawrotami białkomoczu nerczycowego. Przegl Lek 2006, 63, 201–204.
  16. Spadło A, Bodalski J: Zaburzenia gospodarki lipidowej w zespole nerczycowym. Przegl Pediatr 1997, 27, 208–214.
  17. Nowosińska E, Drobnik D, Czekalski S: Glomerulopatia lipoproteinowa. Nefrol Dializoter Pol 2000, 4, 205–207.
  18. Dijkman H, Wetzels J, Gemmink J, Baede J, Levtchenko E, Steenbergen E: Glomerular involution in children with frequently relapsing minimal change nephritic syndrome: an unrecognized form of glomerulosclerosis? Kidney Int 2007, 71, 44–52.
  19. Bednarski R, Jasińska B, Stróżecki P, Manitius J: Nefroskleroza – czy nerki są ofiarą ewolucji? Arterial Hypertension 2008, 12, 382–388.
  20. Poręba R, Derkacz A, Poręba M, Andrzejak R: Funkcja śródbłonka u osób z chorobami układu krążenia. Część I: czynniki humoralne i badanie funkcji śródbłonka. Arterial Hypertension 2005, 9, 294–300.
  21. Bełtowski J: Protein homocysteinylation: a new mechanism of atherogenesis? Postępy Hig Med Dosw 2005, 59, 392–404.
  22. Surdacki A: L-Arginine Analogs – inactive markers or active agents in atherogenesis? Cardiovasc Haematol Agents Med Chem 2008, 6, 302–311.
  23. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Böger SM: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000, 87, 99–105.
  24. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP: Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001, 104, 2569–2575.
  25. Książek J, Niemirska A, Lipka M, Grenda R: Ocena grubości kompleksu błona wewnętrzna – błona środkowa naczyń tętniczych u dzieci z idiopatycznym zespołem nerczycowym – doniesienie wstępne. Przegl Lek 2006, 63, 205–207.
  26. Ardigo D, Stüehlinger M, Franzini L, Valtueña S, Piatti PM, Pachinger O, Reaven GM, Zavaroni I: ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 2007, 37, 263–269.
  27. Pełkowska A, Sancewicz-Pach K: Ocena funkcji śródbłonka u dzieci z zespołem nerczycowym w różnych stadiach choroby. Wiad Lek 2005, 58, 35–37.
  28. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99, 3092–3095.
  29. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106, 987–992.
  30. Silva JM, Oliveira EA, Marino VS, Oliveira JS, Torres RM, Ribeiro AL, Simal CJ, Ribeiro MC: Premature acute myocardial infarction in a child with nephrotic syndrome. Pediatr Nephrol 2002, 17, 169–172.
  31. Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, Perani G, Martini A: Nephroticrange proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000, 43, 1405–1409.
  32. Abedini S, Meinitzer A, Holme I, März W, Weihrauch G, Fellstrøm B, Jardine A, Holdaas H: Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010, 77, 44–50.
  33. Lücke T, Kanzelmeyer N, Chobanyan K, Tsikas D, Franke D, Kemper MJ, Ehrich JH, Das AM: Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2008, 23, 734–740.
  34. Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J: ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008, 19, 388–395.
  35. Kielstein J, Fliser D: Do sea star have low ADMA levels? High ADMA and low EPC count – duo infernal for the kidney? Nephrol Dial Transplant 2010, 25, 3138–3141.
  36. Aslam S, Santha T, Leone A, Wilcox C: Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end – stage renal disease patients on hemodialysis. Kidney Int 2006, 70, 2109–2115.
  37. Napora M, Zdrojewski Z: Rola asymetrycznej dimetylargininy (ADMA) w chorobach nerek. Nefrol Dial Pol 2007, 11, 70–73.
  38. Krawczyk R, Weyde W, Krajewska M, Madziarska K, Piasecka-Grzeszek A, Solska U, Klinger M: Elevated ADMA levels are an early event in chronic hemodialysis patients. Adv Clin Exp Med 2008, 17, 191–196.
  39. Napora M, Zdrojewski Z: Asymetryczna dimetylarginina (ADMA) jako czynnik ryzyka powikłań sercowo-naczyniowych u chorych z przewlekłą niewydolnością nerek. Nefrol Dial Pol 2007, 11, 121–125.
  40. Kuwai T, Hayashi J: Nitric oxide pathway activation and impaired red blood cell deformability with hypercholesterolemia. J Atheroscler Thromb 2006, 13, 284–286.
  41. Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q, Galuppo P, Kneitz S, Mayr M, Ertl G, Bauersachs J, Thum T: Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res 2010, 107, 138–143.
  42. Zoccali C, Benedetto F, Maas R: Asymmetric dimethylarginne, C-reactive protein and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002, 13, 490–496.
© Wroclaw Medical University